Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

S8451

Sigma-Aldrich

Saquinavir mesylate

≥98% (HPLC), powder

Sinonimo/i:

(2S)-N1[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-Dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide methanesulfonate, Ro-31-8959

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C38H50N6O5·CH4O3S
Numero CAS:
149845-06-7
Peso molecolare:
766.95
Numero MDL:
MFCD00944907
Codice UNSPSC:
12352200
ID PubChem:
329824603

Livello qualitativo

100

Saggio

≥98% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

desiccated

Colore

white to tan

Solubilità

DMSO: ≥5 mg/mL

Ideatore

Roche

Temperatura di conservazione

2-8°C

Stringa SMILE

CS(O)(=O)=O.CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(N)=O)NC(=O)c4ccc5ccccc5n4

InChI

1S/C38H50N6O5.CH4O3S/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29;1-5(2,3)4/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49);1H3,(H,2,3,4)/t26-,27+,30-,31-,32-,33+;/m0./s1
IRHXGOXEBNJUSN-YOXDLBRISA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Saquinavir is a peptidomimetic hydroxyethylamine inhibitor, which is used to treat human immunodeficiency virus (HIV) infection.

Applicazioni

Saquinavir mesylate may be used in cell signaling and immunology studies.

Azioni biochim/fisiol

Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy. It inhibits both HIV-1 and HIV-2 proteases. Studies have also looked at saquinavir as a possible anti-cancer agent.

Caratteristiche e vantaggi

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Sigma-Aldrich

Sigma-Aldrich

SML1222

Lopinavir

Lonafarnib ≥98% (HPLC)

Sigma-Aldrich

SML1457

Lonafarnib

Abacavir sulfate ≥98% (HPLC)

Sigma-Aldrich

SML0089

Abacavir sulfate

Cepharanthine ≥95% (HPLC)

Sigma-Aldrich

SML1269

Cepharanthine

vibrant-m

Y0001498

Lopinavir

Lamivudine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1365

Lamivudine

Paroxetine hydrochloride hemihydrate ≥98% (HPLC), powder

Sigma-Aldrich

P9623

Paroxetine hydrochloride hemihydrate

Can inhibition of proteasomes or NF-kappaB help control idiopathic nephrotic syndrome?
Scott E Wenderfer
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 27(5), 1698-1701 (2012-05-02)
Rowena E Martin et al.
Antimicrobial agents and chemotherapy, 56(5), 2283-2289 (2012-02-23)
The antiretroviral protease inhibitors (APIs) ritonavir, saquinavir, and lopinavir, used to treat HIV infection, inhibit the growth of Plasmodium falciparum at clinically relevant concentrations. Moreover, it has been reported that these APIs potentiate the activity of chloroquine (CQ) against this
Rosanna Coppo et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 27(5), 1902-1910 (2012-03-21)
Some difficult cases of idiopathic nephrotic syndrome (NS) have been treated with a HIV protease inhibitor provided with proteasome-inhibiting activity. The objective of this study was to limit nuclear factor κB (NF-κB) activation which is up-regulated in these patients, aiming
Ana Beloqui et al.
Journal of controlled release : official journal of the Controlled Release Society, 166(2), 115-123 (2012-12-26)
The aims of this work were (i) to evaluate the potential of nanostructured lipid carriers (NLCs) as a tool to enhance the oral bioavailability of poorly soluble compounds using saquinavir (SQV), a BCS class IV drug and P-gp substrate as
Danijela Maksimovic-Ivanic et al.
Immunologic research, 52(1-2), 157-168 (2012-03-13)
Development of resistance to TRAIL-induced toxicity is one of the strategies used from tumor cells to escape destruction from the immune system. This process may occur through aberrant expression of functional receptors, overexpression of decoy receptors on tumor cell membrane
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.